Revolutionizing antibody discovery for pharma with single cell approaches and LIBRA-seq

Enter text here.

Traditional antibody discovery programs in pharma typically yield only a limited number of candidates while requiring significant time, effort, expensive automation, and consumables. In this webinar, you’ll learn how to accelerate your antibody discovery program using LIBRA-seq (linking B cell receptor to antigen specificity through sequencing), a high-throughput approach that was recently described by researchers at Vanderbilt University. Using this method in conjunction with the 10x Genomics Chromium Single Cell Immune Profiling Solution with Feature Barcoding technology, they were able to capture and analyze thousands of B cells at single cell resolution, resulting in the rapid discovery of thousands of high-quality antibody candidates.

In this webinar, you will learn:
  • An overview of the Chromium Single Cell Immune Profiling Solution workflow and how it compares to traditional drug discovery approaches, such as hybridoma generation
  • How LIBRA-seq was used to discover novel broadly neutralizing anti-HIV mAbs with therapeutic potential
  • Leveraging LIBRA-seq and related technologies to isolate, characterize, and engineer native, paired, full-length, fully human antibodies for pharma programs
  • Applying LIBRA-seq to re-engineer existing antibodies and augment existing antibody portfolios
  • Performing epitope mapping with antigen mutants to study antibody binding to globally representative variants of proteins
The webinar will consist of a ~40 minute presentation followed by a live Q&A session.

Can't make it live? No problem, register here and we'll send you an email when the recording is available.